Form 4: BeOne Medicines Executive Sells Shares for Tax Withholding

BeOne Medicines SVP, General Counsel Henry Lee sold 590 American Depositary Shares due to mandatory tax withholding upon vesting of restricted share units.

Summary

• Henry Lee, SVP, General Counsel of BeOne Medicines Ltd., reported a transaction on June 16, 2026.
• The transaction involved the sale of 590 American Depositary Shares (ADS).
• Each ADS represents 13 Ordinary Shares.
• The sale was executed under a mandatory tax withholding provision related to a restricted share unit award.
• This occurred in connection with the vesting of these restricted share units.
• The sale price was $265.975 per ADS.
• Following this transaction, Mr. Lee beneficially owns 338,884 Ordinary Shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive selling shares can sometimes raise concerns, the stated reason of mandatory tax withholding for vested restricted stock units is a standard and expected event.

Negatives

• A sale of company stock by a senior executive, even if for tax purposes, can sometimes be perceived negatively by the market.

Risks

• The filing does not explicitly mention any new risks. However, the sale of shares by an executive could be interpreted as a lack of confidence, though the reason provided is tax withholding.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and often relate to compensation plans, such as restricted stock units. The specific reason for this sale, mandatory tax withholding, is a common occurrence when equity awards vest and is generally not indicative of a negative outlook on the company's performance.

Stakeholder Impact

• Shareholders: The sale is a small number of shares by an executive and is attributed to tax obligations, so the direct impact on share price is likely minimal. However, any insider selling can be a point of observation for investors.
• Employees: This transaction relates to executive compensation and vesting schedules, which are part of the company's overall compensation strategy.
• Management: The transaction reflects the standard execution of executive compensation plans.

Next Steps

• Continued vesting of remaining restricted share units on subsequent anniversaries of June 15, 2023, subject to continued service.
• Potential for future tax withholding sales as more restricted share units vest.

Key Dates

Keywords

BeOne Medicines, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, SEC Filing, ONC